{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["131"],"submitter":["Su L"],"pubmed_abstract":["Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-? using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-?B activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-? and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS."],"journal":["Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"],"pagination":["110643"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7443334"],"repository":["biostudies-literature"],"pubmed_title":["Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents."],"pmcid":["PMC7443334"],"pubmed_authors":["Zhuang CL","Wang ZB","Kong DP","Su L","Zhang CX","Tu Y","Chen DG","Zhang WN"],"additional_accession":[]},"is_claimable":false,"name":"Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.","description":"Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-? using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-?B activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-? and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2020-11-01T08:21:57Z","creation":"2020-08-29T07:28:28Z"},"accession":"S-EPMC7443334","cross_references":{"pubmed":["32846329"],"doi":["10.1016/j.biopha.2020.110643"]}}